Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BG00002-E · 1 trial · 1 indication
Negative: no detectable antibody at all post-baseline visits. Persistent positive: antibody positive at 2 or more post-baseline visits at least 42 days apart, or positive at the last post-baseline visit. Transient positive: antibody positive at only 1 post-baseline visit prior to the last visit.
| Arm | Type | Description |
|---|---|---|
| Natalizumab High Titer | EXPERIMENTAL | natalizumab high titer 300 mg administered as intravenous (IV) infusion over 60 minutes once every 4 weeks for up to 9 doses |
| Name | Type | Description |
|---|---|---|
| BG00002-E (natalizumab high titer) | BIOLOGICAL | - |
Inclusion Criteria: * Diagnosis of a relapsing form of MS * Must fall within the therapeutic indications stated in the locally approved label for natalizumab * Other protocol-defined inclusion criteria may apply Exclusion Criteria: * Prior treatment with natalizumab * Considered by investigator t...
BG00002-E is a monoclonal antibody being developed for the treatment of Multiple Sclerosis. It is currently in Phase 2 clinical development and is being studied in patients with this condition.
BG00002-E is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being investigated for its potential role in treating Multiple Sclerosis.
BG00002-E is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
BG00002-E is in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 2 trial has been completed.
BG00002-E has been studied in a completed Phase 2 clinical trial with the identifier NCT00516893. This trial, titled 'Natalizumab High Titer Immunogenicity and Safety', enrolled 113 participants with Multiple Sclerosis in the United States.
BG00002-E is a monoclonal antibody being developed for Multiple Sclerosis. The completed clinical trial for BG00002-E was titled 'Natalizumab High Titer Immunogenicity and Safety', but it has not been confirmed whether BG00002-E is the same as natalizumab.